Pier Luigi Zinzani

Also affiliated with University of Bologna

Medicine

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 6%percentile

0.208Author DataRank

Indexed papers

6in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Why this DataRank?

An author's DataRank is the sum of the DataRanks of all 6 indexed papers attributed to them. A prolific author with many moderate-impact papers can outrank one with a single high-impact paper.

Author scores recompute whenever paper DataRanks are refreshed, so this number lags the underlying paper scores by at most one batch run.

Read the full methodology →

The highest-impact dataset this researcher has shared, ranked by DataRank — the single contribution doing the most to lift their data-sharing standing.

Development of a distributed international patient data registry for hairy cell leukemia

Leukemia & lymphoma/Leukemia and lymphoma(2022)10.1080/10428194.2022.2109157

Top 65%

0.208DataRank

Top 65%3 citations

Mirela Anghelina, Jasmine Neal, James S. Blachly, Puneet Mathur, Omkar Lele +38 more

Papers

Driven by 25 papers — median percentile 35. Top paper: “Moxetumomab pasudotox in heavily pre-treated patients with relapsed/refractory hairy cell leukemia (HCL): long-term follow-up from the pivotal trial”.

Moxetumomab pasudotox in heavily pre-treated patients with relapsed/refractory hairy cell leukemia (HCL): long-term follow-up from the pivotal trial

Journal of Hematology & Oncology(2021)10.1186/s13045-020-01004-y

N/A

1.9DataRank · unranked

86 citations

Robert J. Kreitman, Claire Dearden, Pier Luigi Zinzani, Julio Delgado, Tadeusz Robak +14 more

Patient-reported quality of life in patients with relapsed/refractory cutaneous T-cell lymphoma: Results from the randomised phase III ALCANZA study

European Journal of Cancer(2020)10.1016/j.ejca.2020.04.010

N/A

1.3DataRank · unranked

30 citations

H. Miles Prince, Sean Whittaker, Sarah McCue Horwitz, Youn H. Kim, Julia Scarisbrick +22 more

The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee

Blood(2022)10.1182/blood.2022015851

N/A

1.1DataRank · unranked

1538 citations

Elaine S. Jaffe, James R. Cook, Leticia Quintanilla‐Martínez, Steven H. Swerdlow, Kenneth C. Anderson +68 more

Role of stem cell transplant in CD30+ PTCL following frontline brentuximab vedotin plus CHP or CHOP in ECHELON-2

Blood Advances(2022)10.1182/bloodadvances.2020003971

N/A

1.1DataRank · unranked

40 citations

Steven M. Horwitz, Ranjana H. Advani, Jacob Haaber Christensen, Eva Domingo‐Doménech, Giuseppe Rossi +19 more

Nivolumab combined with brentuximab vedotin for R/R primary mediastinal large B-cell lymphoma: a 3-year follow-up

Blood Advances(2023)10.1182/bloodadvances.2023010254

N/A

0.960DataRank · unranked

38 citations

Armando Santoro, Giuseppe Gritti, Pauline Brice, Paul M. Barr, John Kuruvilla +9 more

Atezolizumab, venetoclax, and obinutuzumab combination in Richter transformation diffuse large B-cell lymphoma (MOLTO): a multicentre, single-arm, phase 2 trial

The Lancet Oncology(2024)10.1016/s1470-2045(24)00396-6

N/A

0.903DataRank · unranked

34 citations

Anna Maria Frustaci, Adalgisa Condoluci, Marta Coscia, Roberto Chiarle, Pier Luigi Zinzani +19 more

Allogeneic transplantation after PD-1 blockade for classic Hodgkin lymphoma

Leukemia(2021)10.1038/s41375-021-01193-6

N/A

0.665DataRank · unranked

83 citations

Luca Castagna, Laura Giordano, Vincent T. Ho, Paolo Corradini, Anna Guidetti +61 more

Expression of platelet-derived growth factor receptor α in peripheral T-cell lymphoma not otherwise specified

The Lancet Oncology(2005)10.1016/s1470-2045(05)70213-8

N/A

0.617DataRank · unranked

60 citations

Claudio Agostinelli, Pier Luigi Zinzani, Michele Baccarani, Riccardo Dalla Favera, Stefano A Pileri +1 more

Hairy cell leukemia and COVID-19 adaptation of treatment guidelines

Leukemia(2021)10.1038/s41375-021-01257-7

N/A

0.578DataRank · unranked

46 citations

Leslie A. Andritsos, Versha Banerji, Jacqueline C. Barrientos, Seema A. Bhat, James S. Blachly +34 more

Consensus opinion from an international group of experts on measurable residual disease in hairy cell leukemia

Blood Cancer Journal(2022)10.1038/s41408-022-00760-z

N/A

0.477DataRank · unranked

23 citations

Robert J. Kreitman, Enrico Tiacci, Leslie A. Andritsos, Versha Banerji, Jacqueline C. Barrientos +40 more

Pirtobrutinib monotherapy in Bruton tyrosine kinase inhibitor-intolerant patients with B-cell malignancies: results of the phase I/II BRUIN trial

Haematologica(2024)10.3324/haematol.2024.285754

N/A

0.406DataRank · unranked

14 citations

Michael Wang, Lindsey E. Roeker, Krish Patel, Jennifer A. Woyach, William G. Wierda +30 more

Brentuximab vedotin and chemotherapy in relapsed/refractory Hodgkin lymphoma: a propensity score–matched analysis

Blood Advances(2024)10.1182/bloodadvances.2023012145

N/A

0.391DataRank · unranked

9 citations

Fer de Wit, Alex F. Herrera, Pier Luigi Zinzani, Ann S. LaCasce, Peter D. Cole +12 more

Peripheral T‐cell lymphomas

Hematological Oncology(2023)10.1002/hon.3142

N/A

0.385DataRank · unranked

12 citations

Pier Luigi Zinzani, Alessandro Broccoli

Brentuximab vedotin plus chemotherapy for the treatment of front-line systemic anaplastic large cell lymphoma: subgroup analysis of the ECHELON-2 study at 5 years’ follow-up

Blood Cancer Journal(2025)10.1038/s41408-025-01329-2

N/A

0.282DataRank · unranked

5 citations

Barbara Pro, Tim Illidge, Steven M. Horwitz, Lorenz Truemper, Swaminathan P. Iyer +22 more

Brentuximab vedotin with chemotherapy in adolescents and young adults with stage III or IV classical Hodgkin lymphoma in ECHELON-1

Haematologica(2023)10.3324/haematol.2023.283303

N/A

0.269DataRank · unranked

5 citations

Ann S. LaCasce, Nancy L. Bartlett, David J. Straus, Kerry J. Savage, Pier Luigi Zinzani +7 more

Development of a distributed international patient data registry for hairy cell leukemia

Leukemia & lymphoma/Leukemia and lymphoma(2022)10.1080/10428194.2022.2109157

Top 65%

0.208DataRank

Top 65%3 citations

Mirela Anghelina, Jasmine Neal, James S. Blachly, Puneet Mathur, Omkar Lele +38 more

Association of PET4 response with outcomes of BV-CHP vs CHOP in the ECHELON-2 trial in CD30+ peripheral T-cell lymphoma

Blood Advances(2025)10.1182/bloodadvances.2024015282

N/A

0.185DataRank · unranked

2 citations

Neha Mehta–Shah, Ranjana H. Advani, Nancy L. Bartlett, Jacob Haaber Christensen, Franck Morschhauser +18 more

Lessons learned from experience of phosphatidylinositol 3-kinase inhibitors in chronic lymphocytic leukemia and lymphoma

Haematologica(2025)10.3324/haematol.2025.288114

N/A

0.104DataRank · unranked

1 citations

Pier Luigi Zinzani, Jennifer Brown, Paola Ghione

Safety of Extended Pirtobrutinib Exposure in Relapsed and/or Refractory B-Cell Malignancies

Acta Haematologica(2024)10.1159/000539587

N/A

0.104DataRank · unranked

1 citations

Catherine C. Coombs, Nirav N. Shah, Wojciech Jurczak, Jennifer A. Woyach, Chan Y. Cheah +16 more

A Meta-analysis Investigating Response Rates with Continuous Bruton Tyrosine Kinase Inhibitor Monotherapies in the Treatment of B Cell Lymphomas

Oncology and Therapy(2026)10.1007/s40487-026-00425-y

N/A

0.104DataRank · unranked

1 citations

Rhys Williams, Mei Xue, Binod Neupane, Priccila Zuchinali, Kyle Fahrbach +5 more

855 | A PHASE 3 RANDOMIZED TRIAL: DUVELISIB VERSUS INVESTIGATOR CHOICE (GEMCITABINE OR BENDAMUSTINE) IN RELAPSED/REFRACTORY NODAL T‐CELL LYMPHOMA WITH T‐FOLLICULAR HELPER PHENOTYPE

Hematological Oncology(2025)10.1002/hon.70096_855

N/A

0DataRank · unranked

0 citations

Eva Domingo‐Doménech, David Sidransky, Ohad S. Bentur, Pier Luigi Zinzani, Kate Cwynarski

PATIENT‐REPORTED QUALITY OF LIFE (QOL) FOLLOWING TISAGENLECLEUCEL (TISA‐CEL) INFUSION IN ADULT PATIENTS (PTS) WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA (R/R FL)

Hematological Oncology(2021)10.1002/hon.178_2880

N/A

0DataRank · unranked

1 citations

Michael Dickinson, Joaquín Martínez‐López, Arne Kolstad, Stephen J. Schuster, Martin Dreyling +29 more

Metabolic profile evolution in relapsed/refractory B-cell non-Hodgkin lymphoma patients treated with CD19 chimeric antigen receptor T-cell therapy and implications in clinical outcome

Haematologica(2024)10.3324/haematol.2024.285154

N/A

0DataRank · unranked

3 citations

Laura Del Coco, Federica De Castro, Anna Maria Giudetti, Beatrice Casadei, F Iannotta +26 more

Comparison of immunohistochemistry and gene expression profiling subtyping for diffuse large B‐cell lymphoma in the phase III clinical trial of R‐CHOP ± ibrutinib

British Journal of Haematology(2021)10.1111/bjh.17450

N/A

0DataRank · unranked

12 citations

Songbai Wang, Christopher Major, Brendan P. Hodkinson, Michael Schäffer, Laurie H. Sehn +10 more

398 | LACUTAMAB IN PATIENTS WITH RELAPSED AND/OR REFRACTORY MYCOSIS FUNGOIDES: LONG TERM FOLLOW‐UP AND TRANSLATIONAL DATA FROM THE TELLOMAK PHASE 2 TRIAL

Hematological Oncology(2025)10.1002/hon.70094_398

N/A

0DataRank · unranked

0 citations

Martine Bagot, C. Ram‐Wolf, Auris Huen, Stéphane Dalle, Neha Mehta–Shah +16 more

Pier Luigi Zinzani

Indexed papers

Top data-sharing exemplar

Papers